News
Tempus AI Bets on MRD Testing Growth With Personalis Acquisition
Key Points
- Interested in Tempus AI, Inc.? Here are five stocks we like better.
- Tempus AI plans to acquire Personalis to bolster its minimal residual disease, or MRD, testing business and
Tempus AI Aktie: Personalis-Übernahme schickt Kurs 10% runter
Tempus AI greift nach dem Diagnostik-Spezialisten Personalis. Die Nachricht schickt die Aktie des KI-Unternehmens…
Der Beitrag Tempus AI Aktie: Personalis-Übernahme schickt Kurs 10% runter erschien
Personalis Q1 Earnings Call Highlights
Personalis (NASDAQ:PSNL) reported first-quarter 2026 revenue of $15.5 million as management said the company is prioritizing growth in
Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors?
Christopher M. Hall, Chief Executive Officer of Personalis (NASDAQ:PSNL), disclosed the direct exercise and immediate sale of 100,000 shares of Common Stock, valued at approximately $1.10 million
Personalis (PSNL) Q2 Revenue Falls 24%
Personalis (NASDAQ:PSNL), a precision genomics company focused on ultra-sensitive minimal residual disease (MRD) detection and comprehensive tumor profiling for cancer, reported its second-quarter